Table 1

Absolute and relative frequencies

A. Absolute and relative frequencies of 459 patients by phase of clinical trial, gender, and agent
VariableCategoryPatientsPercentage
PhaseI27559.9
I/II245.2
II16034.9
GenderF15333.3
M30666.7
AgentPaclitaxel24553.4
Estramustine15433.6
Carboplatin14030.5
Cisplatin459.8
Docetaxel4810.5
Irinotecan367.8
Tomudex367.8
Tipifarnib (R115777)a347.4
5-Flourouracil306.5
Gemcitabine194.1
Topotecan143.0
Cytoxan132.8
Vinblastine122.6
Bryostatin122.6
BMS-188797b112.4
BMS-214662a112.4
B. Absolute and relative frequencies of 459 patients by highest toxicity grade
Highest toxicity
OverallNo toxicity102.2
18418.3
211625.3
313930.3
411024.0
NonhematologicalNo toxicity439.4
114732.0
212126.4
311024.0
4388.3
HematologicalNo toxicity11424.8
16814.8
210522.9
38017.4
49220.0
C. Absolute and relative frequencies of 459 patients by primary disease site, prior chemotherapy or radiotherapy, performance status, alcohol use, cigarette smoking, and weight loss
VariableCategoryPatientsPercentage
Primary disease siteProstate11725.55
Other10322.49
Lung7315.94
Ovary429.17
Colon418.95
Esophageal398.52
NHL204.37
Pancreas143.06
Breast91.97
Prior radiation<25%45399.34
>25%30.66
Prior chemotherapyNo22649.24
Yes23350.76
Performance status017739.16
125255.75
2235.09
Alcohol useNo18245.61
Yes21754.39
Cigarette smokingNo16841.38
Yes23858.62
Weight lossNo34476.27
Yes10723.73
  • a Farnesyltransferase inhibitor.

  • b Taxol analog.